{ "Study of ORKA-002 for Moderate-to-Severe Plaque Psoriasis", "This study is testing a new medication called ORKA-002 for people with moderate-to-severe plaque psoriasis. Researchers want to find the best dose of ORKA-002 and see how well it works and if it's safe. You might be able to join if you are between 18 and 79 years old, have had plaque psoriasis for over 6 months, and your psoriasis covers at least 10% of your body. The main goals are to see how many participants achieve clear skin (100% reduction in PASI score) by Week 16 and to track any side effects over 48 weeks. This study is currently looking for participants.", "design": "This is a randomized, double-blinded, placebo-controlled study involving about 160 adults. This means participants will be randomly assigned to receive either ORKA-002 at different doses or a placebo (an inactive substance), and neither you nor your doctor will know which you are receiving.", "commitments": "The study involves a screening period, an induction period where you receive treatment, and a post-treatment follow-up period. ORKA-002 or placebo will be given by injection under the skin.", "compensation": "Not stated in the trial record.", "follow_up": "You will be followed for side effects from Day 1 through Week 48.", }

Study design

Not specified.

What's involved

Not specified in the trial record.

Compensation

Not stated in the trial record.

Follow-up

Not specified.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.